品名：Seraseq® Unmethylated ctDNA Mutation Mix

货号：0710-3088

品牌：SeraCare 

Product Specifications

% Methylation：<2% 

Fragment Size Peak：155-220 

Concentration：10ng/pL 

Fill Size：25 L 

Total DNA：250 ng 

Buffer：0.1x TE 

Details

The use of ctDNA in the study and treatment of cancer continues to expand. Recent advances have highlighted 

CpG methylation of ctDNA a biomarker with multiple utilities. Methylation status gives insight to tumor 

recurrence, epigenetic regulation of gene expression and may also indicate tissue of origin of ctDNA. 

Despite the impactful layer of information methylation status adds to base-pair level sequencing data and the 

proliferation of assays to incorporate methylation data, reference materials have been limited compared to 

other areas of oncology. Seraseq Unmethylated ctDNA Mutation Mix is a low background ctDNA reference 

material comprised of ctDNA that is unmethylated (<2% detectably methylation) at all cpg sites. 

It can be used on its own or blended with Seraseq Methylated ctDNA mutation mix to create a desired percent 

methylated ctDNA profile. 

维百奥生物代理SeraCare对照及参比物质。

维百奥（北京）生物科技有限公司，自2018年与SeraCare（现隶属于LGC Clinical Diagnostics）合作以来，长期为中国客户

提供包括SeraSeq系列参比物质，领域包括肿瘤、生殖健康和遗传病。SeraCare研发和生产一系列临床参比物质，可以用于任何

研发阶段，以确保临床基因组学检测结果的准确性。

SeraCare参比物质涵盖的范围：

1）Next Generation Sequencing

2）Sanger Sequencing

3）Real-time PCR and digital PCR (dPCR)

4）Microarray

主要特点

1）Ready-to-use reference materials covering clinically-relevant variants and all variant types - SNVs, INDELS, CNVs, 

and RNA fusions

2）Highly multiplexed - provide significantly more data per NGS run, saving sequencing costs

3）Available in multiple formats to suite different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA 

in plasma, and FFPE

4）Manufactured in cGMP-compliant, ISO 13485-certified facilities

5）Stringent product release testing - all variants qualified by dPCR for allele frequencies or copy numbers